Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4161 participants.

Also called NCT01508026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01508026
Other papers using this trial's data
  • Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study Lancet (London, England), 2014-05-31 DOI, PubMed 24881993 PubMed links an erratum for this paper. Erratum: PMID 27673469

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01508026. Randomized; triple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
Condition
Stage 1 Hypertension
Condition
Stage 2 Hypertension
Intervention (Drug)
Nebivolol and Valsartan 1
Intervention (Drug)
Nebivolol and Valsartan 2
Intervention (Drug)
Nebivolol and Valsartan 3
Intervention (Drug)
Nebivolol 1
Intervention (Drug)
Nebivolol 2
Intervention (Drug)
Valsartan 1
Intervention (Drug)
Valsartan 2
Intervention (Drug)
Placebo
Lead sponsor
Forest Laboratories (class: industry)

Record details

Record id
cardio:ct-nct01508026
Content hash
5bc28858d2f5990941f1d1858375846749e43dc1a3c68c357db3089a02ab5f6b